Daiichi Faces Patent Suit Over New Breast Cancer Drug
Daiichi Sankyo is facing claims in Texas federal court that its recently approved breast cancer treatment drug, which has allegedly earned the Japanese pharmaceutical giant $70 million in sales, infringes a...To view the full article, register now.
Already a subscriber? Click here to view full article